Grace Therapeutics, Inc.: 10% owner Opaleye Management Inc. bought 14,632 shares

What happened Opaleye Management, Inc., identified as a 10% owner, purchased a total of 14,632 shares of Grace Therapeutics common stock in open market or private purchases. The Form 4 lists three acquisitions: 2,077 shares at $2.02 for $4,190 on Oct 8, 2026; 5,340 shares at $2.04 for $10,918 on Oct 9, 2026; and 7,215 shares at $2.02 for $14,574 on Oct 12, 2026. The Form 4 was filed on Oct 13, 2026.

Key details

• Transaction dates and prices: Oct 8, 2026 — 2,077 shares @ $2.02 ($4,190); Oct 9, 2026 — 5,340 shares @ $2.04 ($10,918); Oct 12, 2026 — 7,215 shares @ $2.02 ($14,574).
• Total shares purchased: 14,632 shares for a total of $29,682.
• Shares owned after the transaction: not reported in this Form 4.
• Relevant footnotes from the filing:
  • F1: Securities are owned directly by Opaleye, L.P.; Opaleye Management, Inc. is the Fund's investment manager and may be deemed to beneficially own the Fund's securities.
  • F2: A reported price is a weighted average; purchases were made at prices ranging from $2.03 to $2.05 and full per-price breakdown can be provided on request.
  • F3: Opaleye Management, Inc. disclaims beneficial ownership except to the extent of its pecuniary interest.
• Form 4 filing date: Oct 13, 2026. No late filing is indicated in the Form 4.

Why it may matter

• Transaction type: these were purchases (code P), not option exercises, gifts, awards, or tax withholdings.
• Holder type: Opaleye is reported as a 10% owner, which denotes a large holder rather than an executive officer.
• This filing does not show why the insider traded or why the company acted.